Key Takeaways
- Trump’s revocation of a biotechnology order may negatively impact the US bioeconomy and its supporters.
- European countries are seeking increased investment in biotechnology to foster growth and sustainability.
- Advanced biotechnology is projected to generate up to €1 trillion in revenues by 2040 if adequately supported.
Impact of Biotechnology Policy Changes
President Trump’s recent decision to revoke an executive order advancing biotechnology and biomanufacturing may hinder significantly the development of the US bioeconomy. This revocation has raised concerns among Republican senators from Nebraska, Indiana, Maine, Michigan, and Wyoming, all of whom have built robust bioeconomy infrastructures aimed at transitioning from fossil-based industrial processes to energy-efficient, low-carbon alternatives. Observers in Brussels had previously anticipated that Trump would not turn against his supporters, but this action disproves that assumption.
Stakeholders from Europe are proactively encouraging US biotech firms to explore opportunities within the European market, emphasizing the bloc’s strengths in research and development (R&D) related to food technology, biochemical engineering, and protein engineering. Sofie Carsten Nielsen, Director of the European Biosolutions Coalition, highlighted that Europe could become a leader in biosolutions, but this would require substantial public investment to overcome high capital costs and remove regulatory hurdles. She warned that a lack of decisive action could result in missed opportunities for job growth and significant reductions in CO2 emissions.
In 2022, the UK emerged as a key player in bioengineering by integrating artificial intelligence with its bio-based economy framework, enabling advancements in sustainable production methods. Dr. Guillermo Nevot, Chair of the European Synthetic Biology Society, underscored the need for Europe to adopt innovative approaches and support synthetic biology initiatives to maintain competitiveness in the global market.
Meanwhile, France is leading with more than 20 biorefineries, while Italy has allocated €2.2 billion for biorefinery projects through 2027. Germany, too, is poised to invest heavily in the bioeconomy, with its SPRIND think tank advocating for co-investment in promising technologies that combine biotechnology with AI-driven automation to enhance production efficiency.
Germany’s next chancellor, Friedrich Merz, is called upon to allocate funds from a newly established €100 billion climate transformation fund to support projects like Evonik’s Rheticus, which aims to develop renewable energy solutions through innovative processes. Research indicates that with the right backing, advanced biotechnology could lead to an estimated €1 trillion in added revenues by 2040 and contribute to reducing greenhouse gas emissions by 5%, potentially revolutionizing the sector if grounded in updated, AI-driven data metrics.
The content above is a summary. For more details, see the source article.